title: Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations.
authors.affiliation: Global Clinical Research and Development, AstraZeneca LP, Wilmington, Delaware, USA. boaz.hirshberg@astrazeneca.com
authors.forename: Boaz
authors.initials: B
authors.lastname: Hirshberg
authors.forename: Arie
authors.initials: A
authors.lastname: Katz
mesh_terms: D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000517:prevention & control*; D002319:Cardiovascular System / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000188:drug therapy*; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D011379:Prognosis; D012107:Research Design; D016896:Treatment Outcome
chemical_list: D015507:Drugs, Investigational; D007004:Hypoglycemic Agents